Leerink Partnrs Issues Negative Forecast for Biogen Earnings

Biogen Inc. (NASDAQ:BIIB) – Research analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for shares of Biogen in a research report issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now forecasts that the biotechnology company will post earnings of $4.05 per share for the quarter, down from their previous forecast of $4.10. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Leerink Partnrs also issued estimates for Biogen’s Q3 2025 earnings at $3.96 EPS, Q4 2025 earnings at $4.19 EPS, FY2025 earnings at $14.90 EPS and FY2026 earnings at $16.30 EPS.

A number of other analysts have also recently issued reports on BIIB. Morgan Stanley cut their price objective on Biogen from $157.00 to $152.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 9th. Truist Financial lowered their price target on shares of Biogen from $220.00 to $210.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Scotiabank decreased their target price on Biogen from $244.00 to $224.00 and set a “sector outperform” rating on the stock in a research report on Thursday, February 13th. HC Wainwright reduced their price target on Biogen from $300.00 to $241.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Finally, Sanford C. Bernstein began coverage on Biogen in a report on Tuesday, February 11th. They set a “market perform” rating and a $160.00 target price for the company. Eighteen investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $213.15.

Biogen Price Performance

NASDAQ:BIIB opened at $119.26 on Tuesday. The stock has a market capitalization of $17.46 billion, a PE ratio of 10.66, a P/E/G ratio of 1.51 and a beta of 0.06. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.27. The firm has a fifty day simple moving average of $136.21 and a 200 day simple moving average of $153.22. Biogen has a 1-year low of $110.04 and a 1-year high of $238.00.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, topping analysts’ consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%.

Insiders Place Their Bets

In related news, Director Stephen A. Sherwin sold 8,760 shares of the firm’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the completion of the transaction, the director now directly owns 11,318 shares of the company’s stock, valued at approximately $1,697,926.36. This trade represents a 43.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.16% of the stock is owned by company insiders.

Institutional Investors Weigh In On Biogen

A number of hedge funds have recently bought and sold shares of the business. Lee Danner & Bass Inc. bought a new stake in shares of Biogen in the 4th quarter valued at approximately $25,000. Larson Financial Group LLC lifted its position in Biogen by 640.9% in the fourth quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock worth $25,000 after buying an additional 141 shares during the last quarter. Colonial Trust Co SC increased its position in Biogen by 9,300.0% during the fourth quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 186 shares during the last quarter. SRS Capital Advisors Inc. bought a new stake in shares of Biogen in the 4th quarter worth about $33,000. Finally, OFI Invest Asset Management purchased a new stake in Biogen in the 4th quarter worth about $32,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.